NCT06669533Recruiting
Use Misoprostol to Optimize Prevention of Cervical Cancer
Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 840 (estimated)
- First submitted
- 18 Oct 2024
- Start date
- 25 Feb 2025
- Primary completion date
- 4 Nov 2027
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- Cervical cancer
- NCT number
- NCT06669533
What you commit to
- Study type: Interventional
- Planned participants: 840
- From 25 Feb 2025 to the primary completion date, 4 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- With Type 1 or 2 TZ prior to randomization
Other illness
- History of hysterectomy
Other
- Currently pregnant
- Any cancerous lesions
- Active cervicitis
Who the study is looking for
- Diagnosis of Type 3 TZ confirmed on exam prior to randomization
- Age 25 years or older
Age in the registry: 25 years to - · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé Coordinator of this site? Confirm its status | Yaoundé | Cameroon | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.